WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (NASDAQ:INCY) today announced recent progress in its clinical development programs for HIV, diabetes, oncology and inflammation and reported its first quarter 2007 financial results. Paul Friedman, M.D., Incyte’s President and Chief Executive Officer, stated, “We remain on track to deliver clinical trial results from several of our programs this year, including proof-of-concept results for our 11beta-HSD1 inhibitor for diabetes, our sheddase inhibitor for solid cancers, and our JAK2 inhibitors.”
